Alimera Sciences Stock News

Alimera Sciences Inc. (ALIM) shares closed today 10.3% higher than it did at the end of yesterday. The stock is currently up 29.1% year-to-date, up 23.0% over the past 12 months, and down 67.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $5.62 and as low as $4.30 this week.Shares closed 55.5% below its 52-week high and 38.3% above its 52-week low.Trading volume this week was 87.3% higher than the 10-day average and 46.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -488.0% The company's stock price performance over the past 12 months beats the peer average by -310.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Alimera Sciences Inc. (ALIM) shares closed today 10.3% higher than it did at the end of yesterday. The stock is currently up 29.1% year-to-date, up 16.5% over the past 12 months, and down 67.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $5.62 and as low as $4.30 this week.Shares closed 55.5% below its 52-week high and 38.3% above its 52-week low.Trading volume this week was 61.9% higher than the 10-day average and 46.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -488.0% The company's stock price performance over the past 12 months beats the peer average by -243.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partne

ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Erin Parsons to its Board of Directors. Ms. Parsons has more than 20 years of experience working in the ophthalmic industry overseeing scientific strategy, medical communications, advocacy development, and peer-to-peer educational programs, much of this in the retina space.

ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners

Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time

Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The stock price of Alimera Sciences Inc (NASDAQ: ALIM) increased by over 6% today. This is why it happened.

PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILU

ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission

ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmi

ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.

Alimera Sciences' (ALIM) CEO Rick Eiswirth on Q2 2021 Results - Earnings Call Transcript

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -39.20% and -6.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Alimera Sciences (NASDAQ:ALIM) moved higher by 5.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 252.94% year over year to $0.78,